India Merger Acquisition MCA Regulatory Filings — November 01, 2026

Acquisition of Perion Network at US$11.70/share (~US$420M) is EPS accretive by end of first year post-closing, with Perion's US$228M cash and zero debt reducing effective EV to ~US$192M

Combined entity targets FY2028 revenue run-rate of >US$700M, implying a ~2.3x revenue scale-up from the acquisition, with funding secured via committed bank financing and available cash

Go-shop period for Perion may attract competing bids, potentially raising the final price or validating the valuation, though it introduces deal-completion uncertainty

Scheme of Amalgamation of Piombino Steel effective October 31, 2026, with appointed date January 1, 2026, consolidating authorized capital to ₹27,980 crore, enhancing scale and operational synergies

Completed slump-sale acquisition of U M Cables' business undertaking on a going-concern basis, effective October 31, 2026, likely expanding cable manufacturing capacity and market share

Completed 100% acquisition of Sushodha Institute of Gastroenterology, making it a wholly-owned subsidiary, diversifying into healthcare services

Perion's delisting from Nasdaq and TASE upon closing streamlines operations and eliminates dual-listing costs, with integration under the Perion brand preserving customer continuity

NCLT Mumbai Bench final order dated October 16, 2026, and INC-28 filing completed, removing regulatory overhang and allowing management to focus on integration

Business Transfer Agreement executed on September 25, 2026, with completion on October 31, 2026, demonstrating swift execution and minimal deal slippage

Acquisition completed within 8 days of initial intimation (October 24 to November 1, 2026), indicating strong deal momentum and operational readiness

All-cash deal of US$420M funded via committed bank financing increases leverage; integration risk of a NASDAQ-listed target with ~US$228M cash and no debt could strain management bandwidth

Go-shop period may result in a superior proposal, potentially forcing Affle to raise its bid or lose the deal, with breakup fees and transaction costs at risk

EPS accretion guidance is back-end loaded (end of first year post-closing), leaving near-term dilution risk if synergies are delayed or financing costs rise

Amalgamation effective date of October 31, 2026, with appointed date January 1, 2026, creates a 10-month retrospective accounting period, which may complicate financial reporting and tax treatments

No financial consideration or performance metrics disclosed for Piombino Steel, limiting visibility into the value accretion or potential liabilities assumed

Slump sale on a going-concern basis may carry integration and employee retention risks; no financial consideration disclosed, obscuring valuation and return on investment

Acquisition of SIGPL for 1,84,374 shares with no financial consideration or valuation disclosed raises governance and disclosure concerns; integration of a small gastroenterology institute may have limited near-term impact

Three of four filings lack insider activity, capital allocation, or period-comparison data, reducing visibility into management conviction and financial health

Effective EV of ~US$192M for Perion (after deducting US$228M cash) implies a highly attractive valuation at ~0.6x FY2028 revenue run-rate target of US$700M, offering significant upside if integration succeeds

Perion's zero-debt balance sheet and cash pile can be used to pay down acquisition financing, potentially accelerating EPS accretion and reducing net leverage

Go-shop period could flush out competing bids, providing a price discovery catalyst; if no superior proposal emerges, the current deal terms are validated

Consolidation of Piombino Steel expands authorized capital to ₹27,980 crore, providing headroom for future fundraising and strategic initiatives without further shareholder approvals

Retrospective appointed date of January 1, 2026, allows JSW Steel to capture Piombino's earnings for the full year, potentially boosting FY2027 consolidated financials

Acquisition of U M Cables' business undertaking may provide immediate capacity expansion and cross-selling opportunities in the cables and wires segment, with synergies likely to accrete margins

Foray into gastroenterology through SIGPL positions the company in a niche healthcare segment; if scaled, it could become a platform for further healthcare acquisitions

The successful NCLT approvals and swift deal closures (R R Kabel, Arvaya) signal a streamlined regulatory environment, reducing execution risk for future M&A in India

Perion shareholder approval and regulatory clearances expected in early 2027; watch for go-shop outcome and any competing bids by end of 2026 [Date: Early 2027]

Integration updates and EPS accretion trajectory post-closing; monitor bank financing terms and net debt levels [Date: Post-closing 2027]

Financial impact of Piombino Steel amalgamation on FY2027 consolidated results; watch for synergy disclosures and any restructuring charges [Date: Q3 FY2027 earnings]

Post-acquisition operational metrics and margin trends from U M Cables' business; watch for capacity utilization and order book updates [Date: Q3 FY2027 earnings]

Integration of SIGPL and any further healthcare acquisitions; monitor for financial details and governance disclosures [Date: Next quarterly filing]

NCLT approval timelines for other pending schemes; any changes in MCA e-filing processes (INC-28) that could affect deal closures [Date: Ongoing]

Perion's delisting from Nasdaq and TASE expected upon closing; watch for any regulatory hurdles from US/Israel authorities [Date: Early 2027]

Utilization of increased authorized capital for future fundraising or acquisitions; watch for board approvals [Date: FY2027]